Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly-owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver, and manufacture pharmaceutical-grade active pharmaceutical ingredients (APIs) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery Inc. is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide.
Company profile
Ticker
LSDI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
LSDI Manufacturing Inc. • TerraCube International Inc. • 114474 BC Ltd. • Lucy Scientific Discovery (USA) Inc. • LSDI Retail Inc. • Lucy Therapeutic Discoveries Inc. • 1438430 BC Ltd. ...
LSDI stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
22 Apr 24
8-K
Termination of a Material Definitive Agreement
12 Mar 24
424B3
Prospectus supplement
1 Mar 24
EFFECT
Notice of effectiveness
28 Feb 24
8-K
Other Events
27 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Feb 24
S-1/A
IPO registration (amended)
22 Feb 24
10-Q
2024 Q2
Quarterly report
13 Feb 24
S-1/A
IPO registration (amended)
5 Feb 24
S-1
IPO registration
12 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 237.61 k | 237.61 k | 237.61 k | 237.61 k | 237.61 k | 237.61 k |
Cash burn (monthly) | 478.75 k | (no burn) | 535.82 k | 970.32 k | 429.48 k | 107.37 k |
Cash used (since last report) | 3.49 mm | n/a | 3.91 mm | 7.08 mm | 3.13 mm | 783.09 k |
Cash remaining | -3.25 mm | n/a | -3.67 mm | -6.84 mm | -2.89 mm | -545.47 k |
Runway (months of cash) | -6.8 | n/a | -6.8 | -7.0 | -6.7 | -5.1 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Feb 23 | Livio Susin | Common Shares | Other | Acquire J | No | No | 2.4 | 9,309 | 22.34 k | 134,809 |
13 Feb 23 | Assad J Kazeminy | Common Shares | Other | Acquire J | Yes | No | 2.4 | 85,000 | 204.00 k | 85,000 |
13 Feb 23 | Christopher McElvany | Common Shares | Conversion | Acquire C | Yes | No | 2.4 | 366,187 | 878.85 k | 366,187 |
13 Feb 23 | Christopher McElvany | Common Shares | Other | Acquire J | Yes | No | 2.4 | 118,403 | 284.17 k | 118,403 |
13 Feb 23 | Christopher McElvany | 8% Convertible Promissory Note Common Shares | Conversion | Dispose C | Yes | No | 2.4 | 500,000 | 1.20 mm | 0 |
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 May 24
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
17 Apr 24
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
29 Mar 24
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
20 Mar 24
12 Health Care Stocks Moving In Monday's After-Market Session
18 Mar 24